Nicola Delorio
Otolaryngology · Cape May Court House, NJNPI 1922008812
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Merz North America, Inc. accounts for 70.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $1,171 and has fallen 80.6% since, to $227 in 2025.
Across 60 payments — averaging $67.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$3K
- Stryker$805
- AbbVie$201
- Regeneron Healthcare Solutions, Inc.$139
- Revance Therapeutics, Inc.$51
- Optinose US, Inc.$20
What the payments were for
- Speaking & faculty fees$612%
- Travel & lodging$1744%
- Food & beverage$3,82894%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 34 | $2,847 |
| Stryker | 12 | $805 |
| AbbVie(2 entities) | 8 | $201 |
| Regeneron Healthcare Solutions, Inc. | 2 | $139 |
| Revance Therapeutics, Inc. | 3 | $51 |
| Optinose US, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$523
- XPRESS ENT DILATION SYSTEM$247
- SCOPIS ENT$174
- XPRESS LOPROFILE$169
- DUPIXENT$125
How this compares
$4,063 in reported general payments places this provider in the 85th percentile of 232 otolaryngology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 232 | $4,759 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 13 | $1,496 |
| Cefdinir | 78 | $1,097 |
| Ofloxacin | 24 | $936 |
| Montelukast Sodium | 62 | $764 |
| Ipratropium Bromide | 14 | $556 |
| Fluticasone Propionate | 17 | $409 |
| Oxycodone Hcl | 78 | $205 |
| Prednisone | 48 | $129 |
| Methylprednisolone | 31 | $122 |
| Lorazepam | 62 | $71 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Cape May Court House
- Nishant ReddyEast Windsor$133K
- Giant LinFlorham Park$25K
- Samir ShahVoorhees$16K
- Brian BensonHackensack$14K
- Andrew BlitzerHackensack$9K
- Ahmad MahmoudClifton$9K
- Jean EloyNewark$8K
- Ramtin KassirWayne$8K
- Wayne HsuehNewark$7K
- Gregory SmithEvesham$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.